BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MASH / NASH readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in MASH / NASH\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05500222-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT05500222)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pati
 ents With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05500222
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05464784-8091@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tipelukast: Phase 2 readout est. (NCT05464784)
DESCRIPTION:Tipelukast\, phase 2\, Type 2 Diabetes.\nStudy: MN-001 in Non-a
 lcoholic Fatty Liver Disease\, Type 2 Diabetes Mellitus\, and Hypertriglyc
 eridemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tipelukast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05464784
URL:https://assetmemo.bio/drug/tipelukast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491458-236@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HU6: Phase 2 readout est. (NCT07491458)
DESCRIPTION:HU6\, phase 2\, MASH / NASH.\nStudy: A Trial to Investigate Saf
 ety\, Exposure\, and Efficacy of HU6 Compared With Placebo in Adult Partic
 ipants With Metabolic Dysfunction-associated Steatohepatitis (MASH)\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hu6#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07491458
URL:https://assetmemo.bio/drug/hu6#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04951219-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT04951219)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Pat
 ients With Non-alcoholic Fatty Liver Disease (NAFLD)\, MAESTRO-NAFLD-Open-
 Label-Extension (MAESTRO-NAFLD-OLE)\nEstimated primary completion: March 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04951219
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05648214-6782@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:ALN-PNP: Phase 1/2 readout est. (NCT05648214)
DESCRIPTION:ALN-PNP\, phase 1/2\, MASH / NASH.\nStudy: A Trial to Learn if 
 ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participant
 s With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)\nE
 stimated primary completion: 10 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05648214
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06836609-6930@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:ALN-CIDEB: Phase 1/2 readout est. (NCT06836609)
DESCRIPTION:ALN-CIDEB\, phase 1/2\, MASH / NASH.\nStudy: A Study to Evaluat
 e ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated St
 eatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepat
 itis (MASLD/MASH)\nEstimated primary completion: 17 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06836609
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288138-8301@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:ECC4703: Phase 2 readout est. (NCT07288138)
DESCRIPTION:ECC4703\, phase 2\, MASH / NASH.\nStudy: A Study of a Thyroid H
 ormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitiv
 e Amine Oxidase (SSAO) Inhibitor\, Alone and in Combination\, in Adults Wi
 th Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)\nEstim
 ated primary completion: 15 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ecc4703#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07288138
URL:https://assetmemo.bio/drug/ecc4703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143968-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07143968)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: A Study
  to Evaluate the Use of Resmetirom in Participants With MASLD and HIV\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07143968
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512427-6935@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:OPK-88006: Phase 1/2 readout est. (NCT07512427)
DESCRIPTION:OPK-88006\, phase 1/2\, MASH / NASH.\nStudy: Phase 1/2 Study of
  OPK-88006 in Healthy and Presumed MASH Participants\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/opk-88006#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07512427
URL:https://assetmemo.bio/drug/opk-88006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03900429-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rezdiffra (Resmetirom): Phase 3 readout est. (NCT03900429)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 3\, MASH / NASH.\nStudy: A Phase
  3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in P
 atients With NASH and Fibrosis\nEstimated primary completion: January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/resmetirom#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03900429
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221188-6690@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221188)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Clinical S
 tudy to Investigate the Safety and Tolerability of Efimosfermin Alfa Injec
 tion in Participants With Known or Suspected F2- or F3-stage MASH\nEstimat
 ed primary completion: 24 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/efimosfermin-alfa#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07221188
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221227-6690@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280329
DTEND;VALUE=DATE:20280330
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07221227)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-
 confirmed F2- or F3-stage MASH\nEstimated primary completion: 29 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722
 1227
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519475-6912@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Rapirosiran (ALN-HSD): Phase 2 readout est. (NCT05519475)
DESCRIPTION:Rapirosiran (ALN-HSD)\, phase 2\, MASH / NASH.\nStudy: A Precis
 ion Medicine Approach Using Gene Silencing to Treat a Chronic Liver Diseas
 e Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult 
 Participants at Increased Genetic Risk for This Condition\nEstimated prima
 ry completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rapirosiran-aln-hsd#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05519475
URL:https://assetmemo.bio/drug/rapirosiran-aln-hsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419374-1159@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06419374)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Pegozafermin in Participants With Compensate
 d Cirrhosis Due to MASH\nEstimated primary completion: 30 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06419374
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920043-6690@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Efimosfermin alfa: Phase 2 readout est. (NCT06920043)
DESCRIPTION:Efimosfermin alfa\, phase 2\, MASH / NASH.\nStudy: A Study of E
 fimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensa
 ted) Due to MASH\nEstimated primary completion: 3 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06920043
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335601-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07335601)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: Study t
 o Evaluate Resmetirom in Post-Liver Transplant Patients With MASH\nEstimat
 ed primary completion: August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/resmetirom#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07335601
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03884075-11054@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT03884075)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, MASH / NASH.\nStudy: Non-Alcoh
 olic Fatty Liver Disease\, the HEpatic Response to Oral Glucose\, and the 
 Effect of Semaglutide (NAFLD HEROES)\nEstimated primary completion: 31 Aug
 ust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03884075
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795164-175@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:pemvidutide: Phase 3 readout est. (NCT07795164)
DESCRIPTION:pemvidutide\, phase 3\, MASH / NASH.\nStudy: Phase 3 Study of t
 he Efficacy\, Safety\, and Clinical Outcomes of Pemvidutide in MASH\nEstim
 ated primary completion: December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemvidutide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07795164
URL:https://assetmemo.bio/drug/pemvidutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631637-6930@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:ALN-CIDEB: Phase 2 readout est. (NCT07631637)
DESCRIPTION:ALN-CIDEB\, phase 2\, MASH / NASH.\nStudy: Study to Evaluate AL
 N-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohep
 atitis (MASH)\nEstimated primary completion: 29 January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07631637
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318169-1159@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06318169)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study Evaluatin
 g the Efficacy and Safety of Pegozafermin in Participants With MASH and Fi
 brosis (ENLIGHTEN-Fibrosis)\nEstimated primary completion: February 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06318169
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854782-6930@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:ALN-CIDEB: Phase 3 readout est. (NCT07854782)
DESCRIPTION:ALN-CIDEB\, phase 3\, MASH / NASH.\nStudy: Trial to Evaluate AL
 N-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Di
 sease (MASLD)\nEstimated primary completion: 3 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/aln-cideb#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07854782
URL:https://assetmemo.bio/drug/aln-cideb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822181-11054@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290425
DTEND;VALUE=DATE:20290426
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT04822181)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, MASH / NASH.\nStudy: Research 
 Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepa
 titis (NASH)\nEstimated primary completion: 25 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04822181
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850063-119@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:survodutide: Phase 3 readout est. (NCT07850063)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: ELEVATE-LIVER: A Study
  to Test Whether Survodutide Helps Improve Heart Structure and Function in
  People With Overweight or Obesity and Fatty Liver Disease\nEstimated prim
 ary completion: 29 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07850063
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632457-119@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:survodutide: Phase 3 readout est. (NCT06632457)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™ - Cirr
 hosis: A Study to Test Whether Survodutide Helps People With a Liver Disea
 se Called NASH/MASH Who Have Cirrhosis\nEstimated primary completion: 5 Ju
 ne 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0663
 2457
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763015-1161@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rezdiffra (Resmetirom): Phase 2 readout est. (NCT07763015)
DESCRIPTION:Rezdiffra (Resmetirom)\, phase 2\, MASH / NASH.\nStudy: Study o
 f Resmetirom in Children and Adolescents With MASH\nEstimated primary comp
 letion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 smetirom#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07763015
URL:https://assetmemo.bio/drug/resmetirom#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527910-6782@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:ALN-PNP: Phase 2 readout est. (NCT07527910)
DESCRIPTION:ALN-PNP\, phase 2\, MASH / NASH.\nStudy: A Phase 2a Study of AL
 N-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous P
 NPLA3-Related MASLD\nEstimated primary completion: 15 March 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aln-pnp#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07527910
URL:https://assetmemo.bio/drug/aln-pnp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704892-6690@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20301016
DTEND;VALUE=DATE:20301017
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07704892)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Study to I
 nvestigate Safety and Efficacy of Efimosfermin Compared With Placebo in Ad
 ult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-a
 ssociated Steatohepatitis (MASH)\nEstimated primary completion: 16 October
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/efimosfermin-a
 lfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07704892
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632444-119@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:survodutide: Phase 3 readout est. (NCT06632444)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™: A Stu
 dy to Test Whether Survodutide Helps People With a Liver Disease Called NA
 SH/MASH Who Have Moderate or Advanced Liver Fibrosis\nEstimated primary co
 mpletion: 27 December 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632444
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701993-6690@assetmemo.bio
DTSTAMP:20261121T004028Z
DTSTART;VALUE=DATE:20330623
DTEND;VALUE=DATE:20330624
SUMMARY:Efimosfermin alfa: Phase 3 readout est. (NCT07701993)
DESCRIPTION:Efimosfermin alfa\, phase 3\, MASH / NASH.\nStudy: A Pivotal Cl
 inical Study to Investigate the Safety and Efficacy of Efimosfermin Compar
 ed With Placebo in Adult Participants With Compensated Cirrhosis Due to Me
 tabolic Dysfunction-associated Steatohepatitis (MASH)\nEstimated primary c
 ompletion: 23 June 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/efimosfermin-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07701993
URL:https://assetmemo.bio/drug/efimosfermin-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
